Head to Head Analysis: Unicycive Therapeutics (NASDAQ:UNCY) vs. Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) and Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current ratings for Teva Pharmaceutical Industries and Unicycive Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries 1 1 13 0 2.80
Unicycive Therapeutics 1 1 5 0 2.57

Teva Pharmaceutical Industries currently has a consensus price target of $48.15, indicating a potential upside of 9.78%. Unicycive Therapeutics has a consensus price target of $18.25, indicating a potential upside of 400.00%. Given Unicycive Therapeutics’ higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Teva Pharmaceutical Industries.

Earnings and Valuation

This table compares Teva Pharmaceutical Industries and Unicycive Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Teva Pharmaceutical Industries $17.26 billion 2.96 $1.41 billion $0.43 102.01
Unicycive Therapeutics N/A N/A -$26.56 million ($1.75) -2.09

Teva Pharmaceutical Industries has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Teva Pharmaceutical Industries has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500.

Profitability

This table compares Teva Pharmaceutical Industries and Unicycive Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries 2.94% 33.20% 6.59%
Unicycive Therapeutics N/A -91.50% -61.47%

Institutional & Insider Ownership

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Unicycive Therapeutics on 10 of the 13 factors compared between the two stocks.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.